Hogne AB

Hogne AB is a Swedish medtech company developing TrigeNas™, a patented nose-to-brain drug delivery platform designed to transform the nose into a controlled delivery gateway for next-generation CNS therapeutics. TrigeNas™ addresses key limitations of conventional nasal delivery, including dosing variability, inefficient targeting, and drug loss, by turning normal breathing into highly consistent, patient-independent self-dosing.

The platform is built around a unique nasal plug architecture that forms a protected intranasal reservoir and integrates a substance-saving, flow-controlled valve. During inhalation, micro-doses are drawn from the reservoir into optimized deposition zones; during exhalation, unabsorbed drugs are retained, improving dose efficiency and reducing waste. This converts the nasal plug into a programmable drug depot, enabling low-variability nose-to-brain delivery through everyday breathing.

Because the nasal cavity is the only organ in direct contact with the brain, TrigeNas™ is engineered to leverage olfactory, trigeminal, and vascular pathways to achieve rapid and reproducible CNS exposure across small molecules, peptides, and emerging modalities. Hogne AB also commercializes NosePlug®, a CE-marked ENT device that validates the company’s nasal-plug expertise, manufacturing quality, and real-world safety, while TrigeNas™ supports their platform partnering strategy.

quick proposal

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.